A. Laadem

发表

RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1.

Shuo Lin, Haigen Huang, R. Chopra, 2015, Blood.

Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

Yijun Yang, Ravindra Kumar, N. Borgstein, 2013, Journal of clinical pharmacology.

Activin receptor antagonists for cancer-related anemia and bone disease

E. Terpos, M. J. Alexander, M. Sherman, 2013, Expert opinion on investigational drugs.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

M. Cazzola, P. Vyas, G. Mufti, 2020, The New England journal of medicine.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

K. Götze, P. Kiewe, U. Germing, 2017, The Lancet. Oncology.

Sotatercept in patients with osteolytic lesions of multiple myeloma

S. Srinivasan, E. Terpos, M. Sherman, 2014, British journal of haematology.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

E. Neufeld, S. Perrotta, M. Cappellini, 2020, The New England journal of medicine.

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)

C. Gwaltney, M. Cappellini, X. Hu, 2018, American journal of hematology.

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)

C. Gwaltney, M. Cappellini, V. Viprakasit, 2018, American journal of hematology.

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

M. Cazzola, P. Vyas, G. Mufti, 2018, Blood.

Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study

K. Götze, P. Kiewe, U. Germing, 2017 .

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

K. Götze, P. Kiewe, U. Germing, 2016 .

LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY

P. Kiewe, K. Goetze, U. Germing, 2015 .

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

P. Kiewe, K. Goetze, U. Germing, 2015 .

An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2014 .

A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia

A. Mead, S. Verstovsek, T. Gerike, 2019, Blood.

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

E. Neufeld, S. Perrotta, M. Cappellini, 2018, Blood.

Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies

J. Crawford, N. Gabrail, J. Goldschmidt, 2015, Supportive Care in Cancer.

Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes

S. Ritland, S. Zhou, M. Palmisano, 2020, CPT: pharmacometrics & systems pharmacology.

Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study

M. Cappellini, G. Graziadei, A. Taher, 2018, Haematologica.

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies

S. Ritland, M. Sherman, K. Attie, 2016 .

53 LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

K. Götze, P. Kiewe, U. Germing, 2015 .

14 A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) OR NON-PROLIFERATIVE CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ANEMIA REQUIRING TRANSFUSION

A. Stamatoullas, G. Garcia-Manero, D. Steensma, 2015 .

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

J. Cortes, C. Abboud, G. Schiller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia

A. Piga, V. Caruso, P. Ricchi, 2016 .

Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia.

S. Perrotta, A. Piga, F. Longo, 2019, Blood.

Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia

S. Ritland, S. Zhou, M. Palmisano, 2020, Journal of clinical pharmacology.

Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies

S. Ritland, M. Sherman, K. Attie, 2016 .

Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: A population-based study.

A. Fathi, A. Brunner, A. Laadem, 2022, Leukemia research.

High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.

T. Delozier, B. Asselain, C. Gisselbrecht, 2005, European journal of cancer.

MDS-191: Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study

K. Götze, P. Kiewe, U. Germing, 2020 .

A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.

M. Puccio, H. Raftopoulos, R. Knight, 2011, Journal of Clinical Oncology.

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2019, Blood.

Quality of life in patients with β‐thalassemia: A prospective study of transfusion‐dependent and non‐transfusion‐dependent patients in Greece, Italy, Lebanon, and Thailand

M. Cappellini, V. Viprakasit, A. Taher, 2019, American journal of hematology.

LUSPATERCEPT DECREASES TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN REGULARLY TRANSFUSED ADULTS WITH BETA-THALASSEMIA

S. Perrotta, A. Piga, V. Caruso, 2016 .

A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.

S. Verstovsek, T. Gerike, R. Gale, 2018 .

A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

M. Heinrich, S. George, B. V. Van Tine, 2022, Journal of Clinical Oncology.

Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study

S. Perrotta, A. Piga, V. Caruso, 2015 .

Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women

Yijun Yang, Ravindra Kumar, N. Borgstein, 2013, Journal of clinical pharmacology.